Browsing Pathways
Showing 751 -
760 of 605359 pathways
SMPDB ID | Pathway Name and Description | Pathway Class | Chemical Compounds | Proteins |
---|---|---|---|---|
SMP0130626View Pathway |
Thiram Drug MetabolismThiram is a drug that is not metabolized by the human body as determined by current research and biotransformer analysis. Thiram passes through the liver and is then excreted from the body mainly through the kidney.
|
|
||
SMP0143818View Pathway |
Thiothixene Drug Metabolism Action Pathway |
Drug Action
|
|
|
SMP0126580View Pathway |
Thiothixene Dopamine Antagonist Action PathwayThiothixene is an antipsychotic of the thioxanthene series. Thiothixene acts as an antagonist (blocking agent) on different post-sysnaptic receptors -on dopaminergic-receptors (subtypes D1, D2, D3 and D4 - different antipsychotic properties on productive and unproductive symptoms), on serotonergic-receptors (5-HT1 and 5-HT2, with anxiolytic, antidepressive and antiaggressive properties as well as an attenuation of extrapypramidal side-effects, but also leading to weight gain, fall in blood pressure, sedation and ejaculation difficulties), on histaminergic-receptors (H1-receptors, sedation, antiemesis, vertigo, fall in blood pressure and weight gain), alpha1/alpha2-receptors (antisympathomimetic properties, lowering of blood pressure, reflex tachycardia, vertigo, sedation, hypersalivation and incontinence as well as sexual dysfunction, but may also attenuate pseudoparkinsonism - controversial) and finally on muscarinic (cholinergic) M1/M2-receptors (causing anticholinergic symptoms like dry mouth, blurred vision, obstipation, difficulty/inability to urinate, sinus tachycardia, ECG-changes and loss of memory, but the anticholinergic action may attenuate extrapyramidal side-effects)
|
Drug Action
|
||
SMP0143895View Pathway |
Thiotepa Drug Metabolism Action Pathway |
Drug Action
|
|
|
SMP0130684View Pathway |
Thiotepa Drug MetabolismThiotepa is a drug that is not metabolized by the human body as determined by current research and biotransformer analysis. Thiotepa passes through the liver and is then excreted from the body mainly through the kidney.
|
|||
SMP0144507View Pathway |
Thiosulfuric acid Drug Metabolism Action Pathway |
Drug Action
|
|
|
SMP0126560View Pathway |
Thioridazine Serotonin Antagonist Action PathwayThioridazine is a trifluoro-methyl phenothiazine derivative. Thioridazine blocks postsynaptic mesolimbic dopaminergic D1 and D2 receptors in the brain; blocks alpha-adrenergic effect, depresses the release of hypothalamic and hypophyseal hormones and is believed to depress the reticular activating system thus affecting basal metabolism, body temperature, wakefulness, vasomotor tone, and emesis. Similar to other first-generation or typical antipsychotics, thioridazine is a medication used to treat schizophrenia. Other indications for use include other psychotic disorders, depressive disorders, pediatric behavioral disorders, and geriatric psychoneurotic manifestations. Positive symptoms are believed to manifest as a result of increased levels of dopamine in the mesolimbic pathway. More specifically, thioridazine blocks DA-2 receptors in the mesolimbic pathway, diminishing positive symptoms. Thioridazine is classified as a low potency first-generation antipsychotic, and as such, is relatively sedating. Thioridazine is a substrate of the hepatic enzyme CYP450 2D6 and is also an inhibitor of the same enzyme.
The drug also exhibits activity at muscarinic receptors (most notably the M1 receptor), which is most likely the source of its anticholinergic effects (e.g., dry mouth, constipation, etc.), the alpha 1A adrenergic receptor (which may explain its association with orthostatic hypotension), the H1 histamine receptor (probably accounting for much of its sedating effect), and the hERG gene, which is likely responsible for its cardiotoxicity
|
Drug Action
|
||
SMP0143123View Pathway |
Thioridazine Drug Metabolism Action Pathway |
Drug Action
|
|
|
SMP0126559View Pathway |
Thioridazine Dopamine Antagonist Action PathwayThioridazine is a trifluoro-methyl phenothiazine derivative. Thioridazine blocks postsynaptic mesolimbic dopaminergic D1 and D2 receptors in the brain; blocks alpha-adrenergic effect, depresses the release of hypothalamic and hypophyseal hormones and is believed to depress the reticular activating system thus affecting basal metabolism, body temperature, wakefulness, vasomotor tone, and emesis. Similar to other first-generation or typical antipsychotics, thioridazine is a medication used to treat schizophrenia. Other indications for use include other psychotic disorders, depressive disorders, pediatric behavioral disorders, and geriatric psychoneurotic manifestations. Positive symptoms are believed to manifest as a result of increased levels of dopamine in the mesolimbic pathway. More specifically, thioridazine blocks DA-2 receptors in the mesolimbic pathway, diminishing positive symptoms. Thioridazine is classified as a low potency first-generation antipsychotic, and as such, is relatively sedating. Thioridazine is a substrate of the hepatic enzyme CYP450 2D6 and is also an inhibitor of the same enzyme.
The drug also exhibits activity at muscarinic receptors (most notably the M1 receptor), which is most likely the source of its anticholinergic effects (e.g., dry mouth, constipation, etc.), the alpha 1A adrenergic receptor (which may explain its association with orthostatic hypotension), the H1 histamine receptor (probably accounting for much of its sedating effect), and the hERG gene, which is likely responsible for its cardiotoxicity
|
Drug Action
|
|
|
SMP0144676View Pathway |
Thioredoxin Drug Metabolism Action Pathway |
Drug Action
|
|
|
Showing 751 -
760 of 65006 pathways